Premium
Management of metastatic gastrointestinal stromal tumour in the Glivec era: a practical case‐based approach
Author(s) -
Harrison M. L.,
Goldstein D.
Publication year - 2006
Publication title -
internal medicine journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.596
H-Index - 70
eISSN - 1445-5994
pISSN - 1444-0903
DOI - 10.1111/j.1445-5994.2006.01077.x
Subject(s) - medicine , malignancy , natural history , stromal cell , imatinib , oncology , chemotherapy , pathological , disease , imatinib mesylate , stromal tumor , myeloid leukemia
Gastrointestinal stromal tumour is now recognized as a distinct pathological malignancy and has received much attention over the last few years. Despite almost universal resistance to chemotherapy, a novel therapy, Imatinib, which targets the KIT receptor, has changed the natural history of this disease. We have audited the first 26 consecutive patients with gastrointestinal stromal tumour treated over 4 years at a single institution. A practical guide to the management of common toxicities and drug resistance is reported with a review of the published reports. Many of the strategies used are likely to be widely applicable to the use of targeted therapies in other malignancies.